Two Sigma Investments LP increased its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 17.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,461 shares of the biotechnology company’s stock after purchasing an additional 13,030 shares during the quarter. Two Sigma Investments LP owned 0.18% of bluebird bio worth $15,577,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in BLUE. BNP Paribas Arbitrage SA lifted its holdings in bluebird bio by 6.5% in the third quarter. BNP Paribas Arbitrage SA now owns 5,444 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 330 shares during the period. Teacher Retirement System of Texas lifted its holdings in bluebird bio by 13.4% in the third quarter. Teacher Retirement System of Texas now owns 3,687 shares of the biotechnology company’s stock valued at $506,000 after acquiring an additional 437 shares during the period. Prudential Financial Inc. lifted its holdings in bluebird bio by 12.6% in the third quarter. Prudential Financial Inc. now owns 4,372 shares of the biotechnology company’s stock valued at $600,000 after acquiring an additional 490 shares during the period. HPM Partners LLC lifted its holdings in bluebird bio by 29.0% in the fourth quarter. HPM Partners LLC now owns 2,227 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 500 shares during the period. Finally, Amalgamated Bank lifted its holdings in bluebird bio by 9.6% in the third quarter. Amalgamated Bank now owns 5,735 shares of the biotechnology company’s stock valued at $788,000 after acquiring an additional 503 shares during the period.
Shares of BLUE traded down $7.45 during trading hours on Friday, hitting $162.70. 1,089,011 shares of the stock were exchanged, compared to its average volume of 934,688. bluebird bio Inc has a 12-month low of $74.45 and a 12-month high of $236.17. The stock has a market capitalization of $8,132.40, a price-to-earnings ratio of -21.10 and a beta of 2.16.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The firm had revenue of $4.17 million for the quarter, compared to analysts’ expectations of $7.11 million. During the same quarter in the previous year, the firm posted ($1.88) earnings per share. The firm’s revenue for the quarter was up 169.0% compared to the same quarter last year. sell-side analysts predict that bluebird bio Inc will post -8.39 EPS for the current year.
A number of research analysts have issued reports on BLUE shares. Cantor Fitzgerald decreased their price target on bluebird bio from $122.00 to $113.00 and set an “underweight” rating for the company in a report on Thursday, February 22nd. ValuEngine raised bluebird bio from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub downgraded bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday. Morgan Stanley boosted their price target on bluebird bio from $152.00 to $209.00 and gave the company an “equal weight” rating in a report on Wednesday, March 21st. Finally, William Blair started coverage on bluebird bio in a report on Monday, March 5th. They issued an “outperform” rating and a $242.00 price target for the company. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $195.20.
In related news, insider David Davidson sold 3,522 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $173.61, for a total transaction of $611,454.42. Following the completion of the sale, the insider now directly owns 13,959 shares in the company, valued at $2,423,421.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason Cole sold 25,000 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total value of $4,897,750.00. Following the completion of the sale, the insider now owns 44,798 shares of the company’s stock, valued at $8,776,376.18. The disclosure for this sale can be found here. Insiders have sold 80,034 shares of company stock valued at $15,122,163 over the last quarter. 3.90% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/bluebird-bio-inc-blue-position-increased-by-two-sigma-investments-lp.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.